GSK Investigational Site
Gainesville, Florida, 32605, United States
NCT Number: NCT00439868
This study will be conducted in healthy volunteers to investigate the effect on intraocular pressure of 2 weeks of treatment with 300mg WELLBUTRIN XL/day.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Gainesville, Florida, 32605, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
Matching placebo tablets to WELLBUTRIN XL.
Other names: WellbutrinXL
Time frame: at Day -1, Days 1 & 14.
Time frame: Days-1,1&14
Time frame: Days1,12-14
Time frame: each visit
Time frame: screening,followup
Time frame: Days-2,13-14
Time frame: Day 14
Time frame: Days-2,-1,1,14
GlaxoSmithKline
Industry
A Cross-over Study to Evaluate the Effect of WELLBUTRIN XL on Intraocular Pressure in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01829100
Anxiety Disorders, Depressive Disorder
Piscataway, New Jersey, United States
View Trial DetailsNCT05927987
Anxiety Disorders, Depressive Disorder
Amsterdam, Netherlands
View Trial DetailsNCT06133309
Depressive Disorder, Mental Disorders
Toulon, Var, France
View Trial DetailsNCT01117753
Anxiety Disorder, Anxiety Disorders
Charleston, South Carolina, United States
View Trial Details